Skip to search formSkip to main contentSkip to account menu

Genz-112638

Known as: GENZ 112638 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

eliglustateliglustat tartrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Auf dem Weg zu einer wirklich allgemeinen Psychologie
  • R. Seidel
  • Journal of Psychology
  • 2018
  • Corpus ID: 69630852
In diesem Artikel wird gegen die herkömmliche »Allgemeine Psychologie« der Vorwurf erhoben, dass sie im Wesentlichen eine… 
2013
2013
Non-fasting glucose levels, hemoglobin A1c (HbA1c), and glucose tolerance test of DIO mice treated with Genz-112638.
2010
2010
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy
Gaucher disease is caused by a deficiency of the lysosomal enzyme glucocerebrosidase (acid β-glucosidase), with consequent… 
2010
2010
Increased Hepatic Insulin Action in Diet-Induced Obese Mice Following Inhibition of Glucosylceramide Synthase
Background Obesity is characterized by the accumulation of fat in the liver and other tissues, leading to insulin resistance. We… 
2010
2010
An amorphous form and crystalline form hemitartrate genz 112638 as glucosylceramide synthase inhibitor
A pharmaceutical composition comprising zolpidem salt of a compound represented by the following structural formula… 
2009
2009
Latest data on Genz-112638, an investigational oral therapy for type 1 Gaucher disease: Phase II clinical trial results after 1 year of treatment
2007
2007
24 Genz-112638: A novel orally available ceramide-based inhibitor of glucosylceramide synthase for treating Gaucher disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)